chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe Pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulde; Severe Pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulde; Severe Pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulde; Severe Pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulde; Severe Pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulde; Severe Pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulde; This is a spontaneous report from a contactable consumer or other non hcp. A 56-years-old male patient received bnt162b2 (BNT162B2), dose 2 (Lot number and expiry date was not reported) via an unspecified route of administration at arm left on 26Feb2021 07:00 (at the age of 56-years-old) as a single for covid-19 immunisation. Medical history included hypergammaglobulinemia benign monoclonal, food allergy from an unknown date and unknown if ongoing. Concomitant medication(s) included finasteride taken for an unspecified indication, start and stop date were not reported. Historical Vaccine BNT162B2 dose 1 (lot number and expiry date was unknown) via unspecified route of administration aa a single dose for COVID-19 immunisation. Severe Pain started in injection arm went up neck then into shoulder  in pain for 5 days till a rash came out on fifth day which Doctor said was Shingles - still in nerve pain in left arm and shoulder in 7th week - started 05Mar2021 19:00 pain. Still in nerve pain in left arm and shoulder. Therapeutic measures were taken as a result of severe pain started in injection arm went up neck then into shoulder - in pain for 5 days till a rash came out on fifth day which doctor said was shingles - still in nerve pain in left arm and shoulder. Outcome of the events was not recovered.
Mother reports that child had 105 fever the night he was given Prevnar, Varivax. he was fussy about a week. Pt was not seen in the ER or the clinic for this problem. Mother reported this incident when pt came for his well child appt on 09/14/2005.
I was 6 weeks pregnant. 2 days later after I had my flu vaccine, I started to bleed and lead to miscarriage eventually. I has flu shot yearly with no problem. I never had miscarriage before.
PROQUAD was administered to a 15 year old patient; no additional adverse events were reported; This spontaneous report was received from a registered nurse, regarding a 15 year old patient of unknown age. Information regarding the patient's pertinent medical history, concurrent conditions and concomitant medications, was not provided.   On an unspecified date, the patient was vaccinated with varicella (oka-merck) virus vaccine live (PROQUAD) 0.5 milliliter subcutaneously for prophylaxis, lot number T035393 and expiration date 14-SEP-2021. (strength was not reported). No additional adverse events were reported.
Angioedema, SkinRash, Rash & UrticariaPruritus Narrative:  Other Relevant History:
Patient came today 10/4 after receiving a Shingrix and Prevnar in RT arm and a Fluzone in LT arm on 9/29/2020; patient RT arm swollen with a red bulls eye taking up half her arm from shoulder to elbow
Vomiting, numbness in feet and legs, pain in feet and legs, tiredness, hot and cold flashes, stomach ache
Baseball sized swelling in left armpit. Soft and not painful. The same side of shot.
Post dog bite, received Tdap vaccine on 10-31-2011. Developed redness, fever and hardness at site 24 hours later after vaccination.
Eczema flare up on legs, knees, hands and elbows; blisters on both palms; open and close his hands and is in pain; This spontaneous case was reported by a consumer and describes the occurrence of ECZEMA (Eczema flare up on legs, knees, hands and elbows), BLISTER (blisters on both palms) and PAIN IN EXTREMITY (open and close his hands and is in pain) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026CV1A and 047B21A) for COVID-19 vaccination.     The patient's past medical history included Eczema (hereditary). Concurrent medical conditions included Drug allergy (penicillin). Concomitant products included GABAPENTIN for Sleep disorder and Anxiety.   On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-May-2021, the patient experienced BLISTER (blisters on both palms) and PAIN IN EXTREMITY (open and close his hands and is in pain). On an unknown date, the patient experienced ECZEMA (Eczema flare up on legs, knees, hands and elbows). The patient was treated with CODEINE PHOSPHATE, PARACETAMOL (TYLENOL WITH CODEINE) ongoing since an unknown date for Pain, at a dose of 1 dosage form and CLOBETASOL PROPIONATE (CLOBETASOL [CLOBETASOL PROPIONATE]) at an unspecified dose and frequency. At the time of the report, ECZEMA (Eczema flare up on legs, knees, hands and elbows), BLISTER (blisters on both palms) and PAIN IN EXTREMITY (open and close his hands and is in pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information were Tylenol with Oxycodone, Clobetasol Topical with Gloves was provided. patient was diagnosed with dyshidrotic eczema.   This case was linked to MOD-2021-138262 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 01-Jun-2021: Reporter Email id is added
Slight headache; Sweats; Still a little tender; Low grade fever; Chills; Exhaustion/ completely knocked down; Arm was more sore than after the first dose; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm was more sore than after the first dose), HYPERHIDROSIS (Sweats), TENDERNESS (Still a little tender), PYREXIA (Low grade fever) and CHILLS (Chills) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 041L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No recorded medical history). Concomitant products included METOPROLOL for an unknown indication.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Jan-2021, the patient experienced PAIN IN EXTREMITY (Arm was more sore than after the first dose). On 08-Feb-2021, the patient experienced HYPERHIDROSIS (Sweats), TENDERNESS (Still a little tender), PYREXIA (Low grade fever), CHILLS (Chills) and FATIGUE (Exhaustion/ completely knocked down). On 11-Feb-2021, the patient experienced HEADACHE (Slight headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 09-Feb-2021, HYPERHIDROSIS (Sweats) outcome was unknown, PYREXIA (Low grade fever) and CHILLS (Chills) had resolved. At the time of the report, PAIN IN EXTREMITY (Arm was more sore than after the first dose), TENDERNESS (Still a little tender), FATIGUE (Exhaustion/ completely knocked down) and HEADACHE (Slight headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Feb-2021, Pyrexia: 101.1 (Inconclusive) 101.1 F.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications reported included ellequist and metoprolol.     This case was linked to MOD-2021-043867 (Patient Link).
At 1:03 pm, patient went over to father shortly after being vaccinated and stated "I do not feel well." He sat down and briefly for <1 second became unresponsive. Upon arousing, he was pale in color and clammy to touch. RN (school nurse was at pt. side). Dad and pt. stated he was worked up and nervous before vaccine. Dr. also at pt. side. 1:15pm: Pt. drank 2 juice boxes and color improved to pink, and conversing without problem. Dr. suggested to pt. and father to have pt. lie down when he returns for his 2nd dose in 3 weeks.
The vaccine expired on 10/17/2022 at 2125 and was given on 10/19/2022 at 1630.
Patient admitted to hospital positive for COVID-19; poor oral intake, increasing confusion; patient's condition worsened; comfort measures; DNR/DNI; Patient passed away in the hospital.
Benign fasciculations with neg. EMG. Constant since 10 days after receiving seasonal flu vaccine. No muscle weakness norm CPK
Left arm injection suite i have extreme pain which started yesterday. it only last 15 seconds or so; This is a spontaneous report received from a contactable consumer via COVAES. A 75-year-old male patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EN6208), via an unspecified route of administration, administered in Arm Left on 12Mar2021 (at the age 75-year-old) as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient's medical history and concomitant medication was not reported. The patient experienced left arm injection suite I have extreme pain which started yesterday. It only last 15 seconds or so on 28May2021. Outcome of the event was not recovered.  Follow-up attempts are completed. No further information is expected.  Follow-Up (29Jun2021): Follow-up attempts are completed. No further information is expected.  Follow-Up 05Jul2021: Follow-up attempts are completed. No further information is expected.
Dose was given after expiration date. Expiration date was07/13/2022. Dose administered on 07/26/2022.
Administered expired vaccine to the patient, after the manufacture date of expiration.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered expired vaccine to the patient, after the manufacture date of expiration.) in a 69-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 070H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Apr-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 12-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered expired vaccine to the patient, after the manufacture date of expiration.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered expired vaccine to the patient, after the manufacture date of expiration.) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Date the vial was initially stored in the refrigerator was unknown. The vial did not undergo any temperature excursions. Vaccine manufacture date of expiry reported was 07-Apr-2022. No treatment details were reported   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Non-significant follow-up information received on 08-Jun-2022. Reporter details was updated.
She got her vaccine, didn't have any reaction until the afternoon.  She was extremely tired and all she wanted to do was sleep and her head was hurting.  She took a nap feeling she would feel better, and just kept going back to sleep and going back to sleep.  Her arm hurt, but didn't think it was anything unusual.  During the night she was extremely uncomfortable and hurt incredibly.  The next morning she had sneezing, congestion and extremely sore to cough and burns in her chest/lungs.  She is very congested and coughing.  She thought when she woke up this morning she would feel better, but she does not at all.  She has taken aspirin and has been calling her doctor, but they are not answering the phone yet.  She may have a low grade fever as she feels that her skin is somewhat hot.    She did a COVID test yesterday afternoon that was negative.
Information has been received from a physician concerning a 64 year old male with a history of oral candidiasis when on steroids and no allergies who on 01-MAR-2007 was vaccinated with a dose of Zostavax. There was no concomitant medication. On approximately 04-MAR-2007, "few days after vaccination", the patient experienced shortness of breath, chest tightness, fatigue, dry tongue and rash on hands and arms. It was reported that these symptoms lasted for a week. On approximately 01-APR-2007, one month after vaccination, the patient's rash reappeared and the patient was treated with steroids. The rash was scaly like psoriasis, patchy, dry raised. The rash was not varicella. The patient also had dry eyes, nose and mouth. The symptoms were described as "sjogren like". The physician reported that patient had patchy areas on his tongue and ulcerations. On 08-MAY-2007 the patient was treated for oral thrush. The patient has several unspecified treatments of DIFLUCAN but there was no improvement. The physician thus believed that patient did not have oral thrush. The physician was also trying to determine if the symptoms were an auto immune process. At the time of report patient was not recovered. The patient was also seen by a dermatologist. A product quality complaint was not involved. Diagnostic laboratory test on an unspecified date included a complete blood cell count, erythrocyte sedimentation rate, serum C-reactive protein test and serum rheumatoid factor test. All laboratory values were reported as normal. The patient's experiences were considered to be other important medical events by the reporter. Additional information has been requested.
Dizziness and feeling faint, nausea and vomiting, chilling and headache. Better the next day.
I did not have a reaction to the vaccine. On 07/05/2022, I wasn't feeling well with fatigue, muscle aches, chills, cough and sore throat. On 07/06/2022, I tested positive for COVID-19. I contacted my doctor and was not given a prescription for PAXLOVID because of my age. I am a physician and prescribed myself PAXLOVID.
unusual rash/somewhat painful rash; felt "tight" itchy; stinging; tight"; This case was reported by a nurse via call center representative and described the occurrence of rash in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 22nd April 2019, the patient received the 1st dose of Shingrix. In April 2019, less than a week after receiving Shingrix, the patient experienced rash, itchy rash, stinging and skin tightness. On an unknown date, the outcome of the rash, itchy rash, stinging and skin tightness were unknown.   It was unknown if the reporter considered the rash, itchy rash, stinging and skin tightness to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The retired nurse reportied that he experienced all the side effects listed after he got his Shingrix vaccine.  The patient also describes that he developed an unusual rash in less than a week on his back which felt tight itchy and somewhat painful and stinging after a shower.  The patient saw a dermatologist and she didn't knew what it was. The patient was asked for product lot number and expiration date, but did not have that information. He said he would try to obtain that from pharmacy.
This spontaneous report as received from a Registered Nurse refers to a 18 year old female patient with no pertinent medical history/drug allergies or drug reactions reported. On 20-MAY-2015, the patient was vaccinated with first dose of GARDASIL 0.5 ml (lot# K011562, expiration date: 08-APR-2017) intramuscular in the right arm and the first dose of VAQTA 0.5 ml (lot # K018181, expiration date: 04-JUN-2017) in the left arm. There was no concomitant therapy reported. On the same date, within seconds of completed the dose of GARDASIL, the patient who was sitting on the exam table fell backwards and hit the wall, the patient experienced gait disturbance reported as "the patient was limp at first", tremor reported as "began shaking", musculoskeletal stiffness reported as "became stiff with her arms extended and cross" pallor reported as "turned pale in color". The nurse stated that the patient's oxygen saturation was 99% and that her blood pressure and pulse were normal (results were not provided). The patient stated that she felt better but a little dizzy and nauseated and vomited before left the office. The patient's mother stated that after the patient went home, she took a short nap and woke up ate dinner and felt fine. No treatment was given to the patient and no laboratory test was performed. The nurse stated that an unspecified physician said that the patient would not finish the GARDASIL, due this reaction, but did not specify if she would administer VAQTA to the patient again. The outcome of pallor, nausea, vomiting, dizziness, fall, musculoskeletal stiffness, gait disturbance and tremor was reported as recovered/resolved on the same date. Additional information has been requested.
pt died at home; had a positive COVID test on 1/2/22 and was quarantined at home; family found pt on the floor unresponsive; EMS called; pt in asystole and pronounced deceased at the home; per death certificate, contributing condition was recent COVID 19 infection
administration of Havrix after the vaccines were exposed to freezing temperatures and administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 3-year-old male patient who received HAV (Havrix) (batch number Y3ME2, expiry date 23-FEB-2025) for prophylaxis.   On 06-NOV-2023, the patient received Havrix. On 06-NOV-2023, an unknown time after receiving Havrix, the patient experienced incorrect storage of drug (Verbatim: administration of Havrix after the vaccines were exposed to freezing temperatures and administered). The outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 13-NOV-2023 The reporter contacted GlaxoSmithKline via phone and inquiring about Havrix and what information was available about the administration of Havrix after the vaccines were exposed to freezing temperatures and administered, which led to incorrect storage of vaccine. They gave partial information about vaccines, patient and event.  The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up.
series of emotions; headache; nausea; muscle pain; weakness; fever; confusion; chest pain; light headed; This is a spontaneous report from a non-contactable other hcp (patient). A 21-year-old non pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE,Solution for injection,Batch/Lot number: not reported), via an unspecified route of administration, administered in Arm Right on 15Jun2021 14:00 as DOSE 1, SINGLE for COVID-19 immunisation. Facility type for vaccination was hospital.The patient medical history and concomitant medications were not reported. Patient did not receive other medications in four weeks. No Other medications in two weeks. No covid prior vaccination.The patient previously took ceclor and experienced known allergies: Ceclor. On 15Jun2021 14:00, the patient experienced series of emotions, headache, nausea, muscle pain, weakness, fever, confusion, chest pain, light headed. Patient was not received treatment. No covid tested post vaccination. The outcome of events were not recovered.  No follow-up attempts are possible; Information on lot/batch number cannot be obtained. No further information is expected.
(L) thigh swelling/induration/warmth 7cm x 10cm developed after vaccines 11/22 seen 12/3 in clinic. Appeared cellulitic started on Keflex
got the 2 shots, have had them 3 times since/Suspected vaccination failure; had them 3 times worse than before the shot; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had them 3 times since, and they were far worse than before the shot).   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.     Additional Information: GSK Receipt Date: 14-AUG-2022 Reporter's comment: This case was reported by the patient via interactive digital media. The patient stated that right there with you all. The patient finally got the 2 shots, and was told he/she most likely would never had shingles again, well. The patient have had them 3 times since, and they were far worse than before the shot. The patient stated that he/she could not win. The patient stated good luck all. Additional Supportive Information: This case was considered as suspected vaccination failure as detail regarding laboratory test and time to onset, confirming shingles was unknown at the time of reporting. The follow-up would not possible as no contact details were available.
This is a spontaneous report from a contactable consumer (patient herself).  A 75-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unknown route, on 29Jan2021 (at 14:30) at single dose on the left arm for COVID-19 immunisation, administered at clinic. Relevant medical history included persistent genital arousal disorder. Past drug history included allergy to codeine. The subject was receiving concomitant medications (unspecified). No other vaccine was received in four weeks. On 01Feb2021, the patient developed severe fatigue, inflammation, swelling, and soreness under tongue....5 days and counting (as reported). The events were assessed as non-serious. The patient had not recovered from the events.  Information on the Batch/Lot number has been requested.